Cardinal Health Inc. 10-K Summary (Fiscal Year Ended June 30, 2004)
Business Context and Reporting Period
This Annual Report covers the fiscal year ended June 30, 2004. Cardinal Health is a leading provider of products and services supporting the health care industry, organized into four primary segments: Pharmaceutical Distribution and Provider Services, Medical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services. The reporting period is significantly impacted by an ongoing SEC formal investigation and a U.S. Attorney inquiry regarding accounting practices, specifically revenue classification and cash discount recognition. Consequently, the Company has restated its financial statements for fiscal years 2000 through 2003 and the first three quarters of fiscal 2004.
Key Financial Metrics
| Metric | Fiscal 2004 (Restated) | Fiscal 2003 (Restated) |
|---|---|---|
| Revenue | $65,053.5 million | $56,731.5 million |
| Net Earnings | $1,474.5 million | $1,375.1 million |
| Diluted EPS | $3.35 | $3.03 |
| Operating Earnings | $2,337.3 million | $2,196.0 million |
| Cash Flow from Operations | $2,624.7 million | $1,398.0 million |
| Total Assets | $21,369.1 million | $18,465.1 million |
| Long-Term Debt | $2,834.7 million | $2,471.9 million |
| Shareholders' Equity | $7,976.3 million | $7,674.5 million |
Note: All financial data presented is restated to reflect accounting adjustments identified during the Audit Committee's internal review.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 15% to $65.1 billion, driven by higher sales volume, pharmaceutical price increases (approx. 6%), and acquisitions (notably ALARIS and Intercare). However, growth in the Pharmaceutical Distribution segment was dampened by a business model transition reducing vendor margins.
- Profitability: Net earnings rose 7% to $1.47 billion. Operating earnings grew 6% despite a 1% decline in the Pharmaceutical Distribution segment's operating earnings due to reduced vendor margins and competitive pricing.
- Cash Flow: Operating cash flow nearly doubled to $2.6 billion, primarily due to increased accounts payable (timing of payments) and higher earnings, offset by a decline in inventory investment.
- Acquisitions: The Company acquired ALARIS Medical Systems (IV medication safety) for approximately $2.1 billion and Intercare (European pharmaceuticals) for $570 million. ALARIS results are currently reported in the Corporate segment pending a new segment structure.
- Accounting Restatements: Significant adjustments were made to reclassify "Bulk Deliveries" into "Operating Revenue," change the accounting method for cash discounts, and correct premature revenue recognition in the Automation segment.
Guidance, Outlook, Risks, and Unusual Items
- Business Model Transition: The Pharmaceutical Distribution business is transitioning from a model dependent on inventory price increases to a fee-for-service model. Management has set a deadline of April 1, 2005, for manufacturers to agree to new terms; failure to do so may result in reduced profitability.
- Regulatory Investigations: The Company faces a formal SEC investigation and a U.S. Attorney inquiry regarding revenue classification and accounting practices. Outcomes could include fines, penalties, or criminal proceedings. The Audit Committee has identified "material weaknesses" in internal controls.
- Segment Restructuring: Effective Q1 Fiscal 2005, the Company will create a new "Clinical Technologies and Services" segment, replacing Automation and Information Services and incorporating ALARIS.
- Legal Contingencies: Significant litigation includes shareholder class actions regarding financial disclosures, latex exposure claims (Allegiance), and vitamin antitrust recoveries. The Company believes insurance will cover a substantial portion of latex liabilities.
- Credit Ratings: Credit ratings are BBB/Baa3/BBB+ with "negative" or "on review" outlooks. A downgrade could increase borrowing costs and restrict capital access.
Investor Verification Checklist
- Restatement Scope: Verify the full extent of the restatements for fiscal years 2000-2004 and confirm if the Audit Committee's internal review is complete or if further adjustments are anticipated.
- Investigation Status: Monitor the status of the SEC and U.S. Attorney inquiries for any new subpoenas, settlements, or enforcement actions.
- Business Model Success: Assess the progress of negotiations with pharmaceutical manufacturers regarding the new fee-for-service compensation model and the impact on margins.
- Internal Controls: Review the implementation of new internal controls and the timeline for the independent auditor's attestation on the effectiveness of these controls (required for Fiscal 2005).
- Segment Performance: Analyze the performance of the new Clinical Technologies and Services segment once reporting begins in Fiscal 2005.